Reduction of Treatment Related Mortality After Stem Cell Transplantation In Children and Adolescents with all Undergoing Allogeneic Stem Cell Transplantation: The Value Of Severe Adverse Event Reporting  by Schrauder, A. et al.
80 Poster Session-I0,833 6 0,155 g/cm2 in the second evaluation (p\0,01). The mean
reduction of the BMD was -1.7 6 9.2% in the LS and -1.7 6
3.3% in the WB. Fourteen (35%) patients had a reduction greater
than 5% in LS, 9 (64%) of them were submitted to unrelated allo-
genic HCT, and 10 (71%) developed Graft Versus Host Disease
(GVHD). Nine patients (13%) had a reduction greater than 5% in
lean body mass. Fifteen patients (38%) had insufficient calcium in-
take in the first evaluation and 20 patients (50%) in the second eval-
uation. Seven patients (18%) had insufficient vitamin D intake in the
first evaluation and 12 patients (30%) in the second evaluation. We
found a positive correlation between changes in BMD in the whole
body and changes in body weight (r 5 0,38; p\0,01).
Conclusion: The prevalence of BMD and lean body mass reduc-
tion was high after six months ofHSCT.There was an important de-
crease in the calcium and vitaminD intake. Children and adolescents
undergoing HCT need nutritional intervention and we suggest
a routine BMD evaluation in those who are at risk for reduction in
bone mass.217
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ALL remains one of the most important causes of haematopoietic
stem cell transplantation (HSCT) in children. The outcome of the
procedure depends on several factors e.g.: 1) ALL subtype 2) pre
transplant treatment 3) leukaemia stage at transplantation 4) condi-
tioning regimen and GvH prophylaxis 5) donor selection and 6)
quality of supportive treatment. In a retrospective analysis of popu-
lation-based data prospectively collected we made an attempt to an-
alyse these factors in a Danish context.
Patients:The course of 85 children\18 years diagnosed between
1–1 1992 and Oct 2008 was examined. This cohort constituted all
children with ALL transplanted in Denmark in this period. All pa-
tients were transplanted at the same centre. Forty-five patients re-
ceived first line treatment according to the Nordic NOPHO1992
protocol and 40 patients according to the NOPHO2000 protocol.
Results: A significant improved survival was recorded between
patients pre-treated according to the NOPHO1992 (KM 5y sur-
vival: 51%) and the later NOPHO2000 protocol (KM 5y survival:
70%). Since the overall survival results for the two treatment pro-
tocols are essentially the same the difference in transplant outcome
is supposed to be due to transplant related causes. An analysis of the
causes for this difference showed that predominantly TRM has de-
clined in the later period but the risk for relapse also decreased. The
survival chance of children transplanted with an HLA-id Sib donor
was particularly good with a KM 5y-survival of around 80%.
The survival of patients transplanted with an UD had a KM 5y-
survival of around 60%. Among factors that were found to be
important for the improved survival were the inclusion of etoposide
in the conditioning regimen and the exclusion of MTX for GvH
prophylaxis.
Conclusion: Significant improvement in survival of ALL children
afterHSCThas occurred within the past 16 years. It is presumed that
during recent years patients in need of an HSCT are not in a better
general condition than earlier and do not have a less aggressive dis-
ease. Never the less as well an improvement in TRM as in the risk of
relapse explain the overall improvement in survival.218
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Vienna, AustriaAlthough allogeneic stem cell transplantation (alloSCT) effec-
tively prevents relapse of acute lymphoblastic leukemia (ALL), trans-
plant related mortality (TRM) may counterbalance that beneficial
effect. In 2003 the BFMStudyGroup initiated a prospective interna-
tional multicenter trial. aiming to standardize and harmonize the
SCT procedure in order to minimize risk of TRM. The immediate
reporting of severe adverse events (SAE) is mandatory in this ongo-
ing study and the findings are regularly discussed within study com-
mittee meetings. Here we report on the frequency, incidence and
outcome of SAE’s in study protocol patients who underwent al-
loSCT between September 2003 and June 2008. 262 children and
adolescents with ALL were recruited by 27 participating SCT cen-
ters. Indications for SCT were all high risk leukemia in any remis-
sion. Conditioning regimen was TBI1VP16 for SCT from MSD
(matched sibling donor), TBI1VP161ATG for SCT from MD
(matched donor), and TBI1Flu1VP161ATG for SCT from
MMD (mismatched donor).
Results: Ninetyone forms reported on life threatening, fatal or
unanticipated problems. Most common reported events were acute
respiratory distress syndromes, disseminated viral infections , bac-
terial sepsis and acute GVHD grade III and IV. Veno-occlusive
disease and other life threatening toxicities were rare events.The
day 360-TRM was 5% in the MSD-group, 4% in the MD-group
and 25% in the MMD group. Overall, 25/262 pts died due to treat-
ment related events. Five pts died after MSD-SCT (all had
a MMD-indication): 2 pts experienced multi organ failure (MOF)
due to infections, 2 pts due to severe acute GVHD and 1 pt
because of extensive chronic GVHD. In the MD-group (all were
transplanted from unrelated donors) 11 pts had fatal treatment
associated outcome: 8 infection associated MOF, 1 EBV-
lymphoproliferative disease, 2 cerebral complications of unidenti-
fied origin, 1 severe bleeding). Four/11 pts underwent second SCT
due to primary or secondary graft failure. Six pts died after
MMD-SCT: 2 after a second or third transplant procedure due
to graft failure, all of them were infection-associated (5 viral, 1
Listeria-meningitis). We conclude that the high quality perfor-
mance of participating centers as well as excellent compliance to
the recommended regimen, better diagnostic measures and
(pre-emptive) treatment of infections, and close and prospective
monitoring of all patients may contribute to the reduced TRM
after alloSCT in children with ALL.219
PREVALENCE, RISK FACTORS AND MANAGEMENT OF METABOLIC SYN-
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Background: Metabolic syndrome (MS) is reported to be highly
prevalent in survivors of cancer and allogeneic stem cell transplant
(SCT). TBI, chemotherapy, GVHD and it’s treatment have been
implicated as factors leading to MS after allogeneic SCT.We report
preliminary results of the study which is being done with the objec-
tives 1) to estimate the prevalence ofMS in children followed at a sin-
gle US institution; 2) to analyze risk factors associated with the
development ofMS; and 3) to correlateMSwith other endocrine dis-
orders post-SCT.
Methods: All patients in the follow-up clinic (.1 year post-SCT)
are screened for lipid profile, BP, BMI, waste-hip ratio, microalbu-
minuria. Diagnosis of MS is based on NCEP-ATPIII criteria.
Once diagnosed, patients are retrospectively analyzed regarding de-
mographics, type of SCT, pre-transplant BMI, occurrence and treat-
ment of GVHD, associated endocrine issues. Patients are educated ,
placed on statins and liver function monitored periodically.
Results: 32 patients have been screened till date and 11 (34.3%)
diagnosed with MS. The median age is 15 years (11–20 years); 6 fe-
male and 5 male. The median duration from SCT to diagnosis was
7.5 years (2.5–14.7 yrs). 7 patients received an allogeneic and 4 an au-
tologous SCTwith varied preparative regimens. Themedian BMI at
the time of diagnosis was 22.74 (20.5–36.6). Only 3 (27%) patients
were overweight (BMI. 25) at the time of SCT; there was an aver-
age BMI increase of 5.5 (0.98–9.4) in the interim between SCT and
diagnosis. Hypertriglyceridemia and hypertension were the most
